Products with Anti-Atherosclerotic bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN4619 | Rhamnocitrin |
| 1. Rhamnocitrin and kaempferol can augment cellular antioxidant defense capacity, at least in part, through regulation of HO-1 expression and MAPK signal transduction. 2. Rhamnocitrin and kaempferol not only protect low-density lipoprotein from oxidation but also prevent atherogenesis through suppressing macrophage uptake of oxidized low-density lipoprotein. 3. Rhamnocitrin can enhance the immune function, improve the formation of spleen cells of mice serum hemolysin of chicken red blood cell immune. 4. Rhamnocitrin shows a significant protection against cloudiness in lenses induced by hydrogen peroxide and hydrocortisone in a dose dependent manner, suggests that rhamnocitrin possesses significant anticataract activity and acts most likely due to its antioxidant property. | |
| BCN4641 | Hexahydrocurcumin |
| 1. Hexahydrocurcumin has cytotoxic effect, may prove useful in cancer prevention. 2. Hexahydrocurcumin together with 5-fluorouracil exerts a synergistic effect and may prove chemotherapeutically useful in treating human colon cancer. 3. Hexahydrocurcumin is an anti-atherosclerogenic agent in humans, can inhibit platelet aggregation in the treatment of human platelet-rich plasma. 4. Hexahydrocurcumin has in vitro antioxidant and anti-inflammatory activities, it has potential beneficial effects as a food and/or dietary supplement. | |
| BCN4903 | Norlichexanthone |
| 1. Norlichexanthone can promote the secretion and expression of adiponectin in cultured ST-13 adipocytes, it has the potential to treat and/or prevent lifestyle-related diseases, including metabolic syndrome, type 2 diabetes, atherosclerosis and cardiovascular diseases. 2. Norlichexanthone has antibacterial activity, it shows strong activity against Bacillus subtilis with IC50 in the range of 1-5uM, it also significantly inhibits the growth of methicillin-resistant Staphylococcus aureus with IC50 of 20.95±1.56uM. 3. Norlichexanthone produces significant chemosuppression of parasitaemia, it has antimalarial activity. | |
| BCN4995 | Harpagoside |
| Harpagoside has anti-inflammatory effects, it blocks lipopolysaccharide (LPS)-induced bone loss in an inflammatory osteoporosis model, and it does not prevent ovariectomy-mediated bone erosion in a postmenopausal osteoporosis model, it may lead to a partial prevention of obesity-induced atherosclerosis by attenuating inflammatory responses. Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-κB activation. Harpagoside exerts neuroprotection effect and ameliorates learning and memory deficit appears to be associated, at least in part, with up-regulation of brain-derived neurotrophic factor (BDNF) content as well as activating its downstream signaling pathways, e.g., MAPK/PI3K pathways. | |
| BCN5057 | Loganic acid |
| Loganic acid( 0.7% solution) has a strong intraocular pressure (IOP)-hypotensive effect, it exhibits both sides effect on superoxide generation. Loganic acid also has protective effects on atherosclerosis risk factors in hypercholesterolemic rabbits, it shows significant anti-inflammatory effects decreasing TNF-α and IL-6 activity in serum. | |
